Suraksha Diagnostic Experiences Valuation Grade Change Amidst Market Challenges and Performance Metrics

Suraksha Diagnostic, a small-cap player in the healthcare services sector, has recently undergone a valuation adjustment. The company's current price stands at 286.85, reflecting a decline from its previous close of 292.70. Over the past year, Suraksha has faced challenges, with a year-to-date return of -23.63%, contrasting sharply with the Sensex's gain of 5.36% during the same period.
Key financial metrics for Suraksha include a PE ratio of 44.68 and an EV to EBITDA ratio of 17.97, which position it differently compared to its peers. Notably, companies like Aster DM Healthcare and Krishna Institute are valued significantly higher, with PE ratios of 100.5 and 77.49, respectively. This disparity highlights Suraksha's relatively more favorable valuation in the context of the broader market.

The company's return on capital employed (ROCE) is reported at 23.40%, while its return on equity (ROE) stands at 15.60%. These performance indicators suggest a solid operational efficiency compared to its peers, which may be a point of interest for stakeholders analyzing the healthcare services landscape.